Early Experience with a Boosted PI–Based Single-Tablet Regimen

Compared with a standard PI–based regimen, a boosted PI–based single-tablet regimen including tenofovir alafenamide had similar antiviral efficacy but with improved bone and renal safety.

Despite the need for multiple pills daily, ritonavir-boosted protease inhibitor (PI)–based regimens have been a mainstay for treatment of HIV-infected patients for almost 20 years due to efficacy and a high barrier to resistance. Now, in an industry-sponsored, phase II, placebo-controlled study, researchers have evaluated the efficacy and safety of a PI-based single-tablet regimen (STR) for initial treatment of HIV infection.

Antiretroviral therapy–naive HIV-infected adults with an estimated glomerular filtration rate ≥70 mL/minute were randomized in a 2:1 ratio to receive a boosted PI–based STR (darunavir/cobicistat/FTC/tenofovir alafenamide) or a three-pill cobicistat-boosted PI-based regimen (darunavir/cobicistat/FTC/tenofovir disoproxil …

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Early Experience with a Boosted PI–Based Single-Tablet Regimen

Topics

Reviewing Author